Johnson & Johnson (J&J) closed a transaction to co-lead the Series A funding of TECLens, a start-up developing a nonincisional refractive correction procedure that leverages corneal cross-linking (CXL) to reshape the cornea. Financial terms of the deal were not disclosed.

TECLens’ proprietary therapy delivers UV light directly to the eye from a fiber optic-connected scleral contact lens. Patients receive a treatment that uses a computationally optimized UV pattern and a dose of riboflavin (vitamin B2) that is customized for each eye. The correction effect is monitored in real-time with ultrasound and the result is enhanced precision of the patient’s outcome, according to J&J.

While TECLens will target presbyopia as its initial indication, there is the possibility of expansion into keratoconus, low-order myopia, hyperopia, and astigmatism. TECLens is currently planning the first refractive correction clinical studies of its one-time vision correction treatment.